Efficacy of Qingpeng ointment (a Tibetan medicine) for acute gouty arthritis: a multi-center, randomized, double-blind, placebo-controlled trial.

Autor:	Shang YX; Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.; Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi University of Chinese Medicine, Xianyang, China., Wei SF; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Yang KP; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Liu Y; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Wei S; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Dong X; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Wang XC; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Xie ZM; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Fang RL; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Liang LN; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Li XF; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Xu L; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Chen MZ; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Zhang KX; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Huang JY; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Wang L; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Yang YG; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Liao HL; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Xing GE; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Zheng YP; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Li XF; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Lin JL; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Shi CQ; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Zeng YP; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Mo LD; Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China., Sun F; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Li XP; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Zhang Z; Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China., Chen K; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., He ZC; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Liu JP; Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. liujp@bucm.edu.cn.; The National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, Faculty of Health Science, UiT The Arctic University of Norway, Tromsø, Norway. liujp@bucm.edu.cn.
Jazyk:	angličtina
Zdroj:	BMC complementary medicine and therapies [BMC Complement Med Ther] 2024 Jan 04; Vol. 24 (1), pp. 21. Date of Electronic Publication: 2024 Jan 04.
DOI:	10.1186/s12906-023-04328-7
Abstrakt:	Background: This study aims to assess the efficacy and safety of Qingpeng ointment (QPO), a Tibetan medicine for alleviating symptoms in individuals with acute gouty arthritis (AGA). Methods: This study was a randomized, double-blind, placebo-controlled trial that involved individuals with AGA whose joint pain, as measured on a visual analog scale (VAS) from 0 to 10, was equal to or greater than 3. The participants were randomly assigned to either the QPO or the placebo group and received their respective treatments twice daily for seven consecutive days. In case of intolerable pain, the participants were allowed to use diclofenac sodium sustained-release tablets as a rescue medicine. The primary outcomes measured were joint pain and swelling, while the secondary outcomes included joint mobility, redness, serum uric acid levels, C-reactive protein levels, and the amount of remaining rescue medicine. Any adverse events that occurred during the trial were also recorded. Results: A total of 203 cases were divided into two groups, with balanced baselines: 102 in the QPO group and 101 in the placebo group. For joint pain, differences between the groups were notable in the VAS scores [1.75 (0, 3.00) versus 2.00 (1.00, 3.50); P = 0.038], changes in VAS [5.00 (3.00, 6.00) versus 4.00 (2.00, 6.00); P = 0.036], and disappearance rate [26.47% compared to 15.84%; P = 0.046] after treatment. Concerning joint swelling, significant between-group differences were observed in the VAS scores [1.00 (0, 2.30) versus 2.00 (0.70, 3.00); P = 0.032] and disappearance rate [33.33% compared to 21.78%; P = 0.046] at treatment completion. The QPO group exhibited a statistically significant mobility improvement compared to the placebo group (P = 0.004). No significant differences were found in other secondary outcomes. Five patients, four from the QPO group and one from the other, encountered mild adverse events, primarily skin irritation. All of these cases were resolved after dosage reduction or discontinuation of the medication. Conclusions: Compared to the placebo, QPO exhibits positive effects on AGA by alleviating pain, reducing swelling, and enhancing joint mobility, without causing significant adverse effects. Trial Registration: ISRCTN34355813. Registered on 25/01/2021. (© 2024. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu